Fig. 7

Local and systemic MMP-9 and VEGF in 4T1 + RAW264.7, 4T1 and RAW264.7 intraductally inoculated mice. a, b Primary tumor/mammary gland MMP-9 (a) and VEGF levels (b) at 3 and 5 w p.i. in 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 inoculation group: n = 8 tumors at 3 w p.i. and n = 12 tumors at 5 w p.i.; 4T1 inoculation group: n = 8 tumors at 3 w p.i. and n = 6 tumors at 5 w p.i.; RAW264.7 inoculation group: n = 8 mammary glands at 3 w p.i. and n = 7 mammary glands at 5 w p.i.). c, d Serum MMP-9 (c) and VEGF levels (d) at 3 and 5 w p.i. in 4T1 + RAW264, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 and 4T1 inoculation group: n = 6 sera at 3 and 5 w p.i.; RAW264.7 inoculation group: n = 4 sera at 3 and 5 w p.i.). e CD31 immunohistochemistry on primary tumor sections from 4T1 + RAW264.7 and 4T1 inoculated mice at 1, 3 and 5 w p.i. (n = 5 at each time point and for each inoculation group). All scale bars = 50 μm. All data are presented as the means +/− SEM. NS: not significant, *: P < 0.05, **: P < 0.01, ***: P < 0.001